o2h Ventures

The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services. The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster. The Fund is structured to be S/EIS compliant providing tax breaks for UK taxpayers. The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech's for new ideas in disease areas such as cancer, genomics, anti-ageing and neurosciences amongst others which has led to higher potential exit valuations. The Fund will widen the community of investors that will help expand early stage research in the UK. The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h operate from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies. For more information, please visit- https://o2hventures.com/